Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Non-Current Debt (2016 - 2023)

Avalo Therapeutics filings provide 8 years of Non-Current Debt readings, the most recent being $10.5 million for Q1 2023.

  • On a quarterly basis, Non-Current Debt changed N/A to $10.5 million in Q1 2023 year-over-year; TTM through Mar 2023 was $10.5 million, a N/A change, with the full-year FY2022 number at $13.5 million, down 58.93% from a year prior.
  • Non-Current Debt hit $10.5 million in Q1 2023 for Avalo Therapeutics, down from $13.5 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $32.8 million in Q4 2021 to a low of $10.5 million in Q1 2023.
  • Median Non-Current Debt over the past 4 years was $14.3 million (2019), compared with a mean of $16.9 million.
  • Biggest five-year swings in Non-Current Debt: dropped 0.68% in 2019 and later crashed 58.93% in 2022.
  • Avalo Therapeutics' Non-Current Debt stood at $14.3 million in 2019, then surged by 130.33% to $32.8 million in 2021, then plummeted by 58.93% to $13.5 million in 2022, then dropped by 22.36% to $10.5 million in 2023.
  • The last three reported values for Non-Current Debt were $10.5 million (Q1 2023), $13.5 million (Q4 2022), and $16.5 million (Q3 2022) per Business Quant data.